REG - ValiRx PLC - Exercise of Warrants

ValiRxAnnouncement

19/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260119:nRSS3318Pa&default-theme=true

RNS Number : 3318P  ValiRx PLC  19 January 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

Exercise of Warrants

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health announces it has received
notification for the exercise of warrants over 80,000 ordinary shares in the
Company at an exercise price of 0.5 pence per share providing the Company with
gross proceeds of £400 ("Warrant Exercise").

Application will be made to the London Stock Exchange to admit the 80,000 new
ordinary shares resulting from the Warrant Exercise to trading on AIM.
Admission of the new ordinary shares is expected to occur on or around 23
January 2026.  The new ordinary shares will rank pari passu with the existing
ordinary shares.

For the purposes of the Disclosure and Transparency Rules, following the issue
of shares detailed above as a result of the Warrant Exercise, the enlarged
issued share capital of the Company will comprise 742,801,072 ordinary shares
of 0.1 pence each. The Company does not hold any shares in treasury. The above
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company, under the Disclosure Guidance and
Transparency Rules.

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS **

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3
(https://valirx.com/s/cc8ef3)

For more information, please contact:

 Investor questions on this announcement                                      https://valirx.com/link/exkQJy

 We encourage all investors to share questions on this announcement via our
 investor hub
 ValiRx plc                                                                   Tel: +44 115 784 0025

                                                                              www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                                                       Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)                             Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)                                     Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                                               +44 (0) 115 787 0206

                                                                              www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive                                           lucy@vformation.biz

 Sue Carr - Director                                                          sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBPMLTMTJBBTF



            Copyright 2019 Regulatory News Service, all rights reserved